Quarterly ResultAug 6, 2026, 04:44 PM
Oncology Institute Rebrands to Starling Oncology; Q2 Net Loss Narrows
AI Summary
Starling Oncology, Inc., formerly The Oncology Institute, Inc., reported strong financial improvements for the second quarter and first half of 2026. Total operating revenue for the six months ended June 30, 2026, increased by 37.7% to $308.7 million, driven significantly by its Specialty Pharmacy segment. The company also substantially narrowed its net loss to $12.3 million from $36.6 million in the prior year period, and generated positive cash flow from operations.
Key Highlights
- The Oncology Institute, Inc. rebranded to Starling Oncology, Inc. on August 3, 2026.
- Total operating revenue for the six months ended June 30, 2026, rose 37.7% to $308.7 million.
- Net loss for the six months ended June 30, 2026, narrowed by 66.4% to $12.3 million.
- Basic net loss per share improved to $(0.10) from $(0.35) for the six months.
- Specialty Pharmacy revenue increased 66.4% to $186.1 million for the six months.
- Net cash provided by operating activities was $9.7 million, a significant improvement from a $(15.2) million outflow.
- Cash and cash equivalents increased to $41.1 million as of June 30, 2026.
- Vendor A accounted for 92% of direct costs for the six months ended June 30, 2026.
Price Impact
More from TOI